PedAM
Pediatric Disease Annotations & Medicines
| Disease | neutropenia |
| Phenotype | C0024299|lymphoma |
| Sentences | 10 |
| PubMedID- 22536253 | In a phase i/ii dose-finding study, activity was observed in heavily pretreated nhl and hodgkin lymphoma (hl) patients, with neutropenia (47%) reported as the most frequent grade 3 or 4 toxicity [52]. |
| PubMedID- 24020054 | Treatment of hiv-associated lymphoma is often complicated by prolonged neutropenia and infectious complications, and requires vigorous supervision after chemotherapy, frequent use of growth factors and antibiotics in contrast to treatment of lymphoma in immunocompetent patients. |
| PubMedID- 26532567 | Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with non-hodgkin's lymphoma in greece. |
| PubMedID- 24684228 | We conducted a cohort study to examine the association between a wide variety of chronic comorbidities and risk of febrile neutropenia (fn) in patients with non-hodgkin lymphoma (nhl) from 2000 to 2009 treated with chemotherapy at kaiser permanente southern california. |
| PubMedID- 21074471 | Recent data show that rituximab maintenance therapy significantly increases the risk of both infection and neutropenia in patients with lymphoma or other hematological malignancies. |
| PubMedID- 21472389 | Disseminated cryptococcosis in a non-hodgkin's lymphoma patient with late-onset neutropenia following rituximab-chop chemotherapy: a case report and literature review. |
| PubMedID- 22913768 | Economic costs of chemotherapy-induced febrile neutropenia among patients with non-hodgkin's lymphoma in european and australian clinical practice. |
| PubMedID- 23301757 | Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors. |
| PubMedID- 25252614 | Background: the primary objective was to describe the total direct inpatient costs among solid tumor and lymphoma patients with chemotherapy-induced febrile neutropenia (fn) and the factors that were associated with higher direct cost. |
| PubMedID- 22972488 | Primary prophylaxis with granulocyte colony-stimulating factor (gcsf) reduces the incidence of febrile neutropenia in patients with non-hodgkin lymphoma (nhl) receiving chop chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. |
Page: 1